Published in J Clin Oncol on May 01, 1992
Mitochondrial proliferation and paradoxical membrane depolarization during terminal differentiation and apoptosis in a human colon carcinoma cell line. J Cell Biol (1997) 2.44
Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest (2001) 2.00
RXRalpha-null F9 embryonal carcinoma cells are resistant to the differentiation, anti-proliferative and apoptotic effects of retinoids. EMBO J (1996) 1.75
Blocking activator protein-1 activity, but not activating retinoic acid response element, is required for the antitumor promotion effect of retinoic acid. Proc Natl Acad Sci U S A (1997) 1.47
Different agonist- and antagonist-induced conformational changes in retinoic acid receptors analyzed by protease mapping. Mol Cell Biol (1994) 1.40
9-cis-retinoic acid inhibits activation-driven T-cell apoptosis: implications for retinoid X receptor involvement in thymocyte development. Proc Natl Acad Sci U S A (1993) 1.19
Unconventional therapies for cancer: 5. Vitamins A, C and E. The Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ (1998) 1.08
Induction of differentiation in HL60 cells by the reduction of extrachromosomally amplified c-myc. Proc Natl Acad Sci U S A (1994) 0.98
Inhibitory effects of retinoic acid metabolism blocking agents (RAMBAs) on the growth of human prostate cancer cells and LNCaP prostate tumour xenografts in SCID mice. Br J Cancer (2006) 0.95
A transition in transcriptional activation by the glucocorticoid and retinoic acid receptors at the tumor stage of dermal fibrosarcoma development. EMBO J (1995) 0.92
Retinoic acid inhibition of ex vivo human immunodeficiency virus-associated apoptosis of peripheral blood cells. Proc Natl Acad Sci U S A (1995) 0.90
Retinoic acid induces cells cultured from oral squamous cell carcinomas to become anti-angiogenic. Am J Pathol (1996) 0.89
Phase I trial of ATRA-IV and Depakote in patients with advanced solid tumor malignancies. Cancer Biol Ther (2010) 0.88
The receptor-DNA complex determines the retinoid response: a mechanism for the diversification of the ligand signal. Mol Cell Biol (1996) 0.88
Cyclin D1 and cancer development in laryngeal premalignancy patients. Cancer Prev Res (Phila) (2009) 0.87
Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 in vitro, and causes growth inhibition in xenografts in vivo. J Cell Biol (1996) 0.86
Altered localization of retinoid X receptor alpha coincides with loss of retinoid responsiveness in human breast cancer MDA-MB-231 cells. Mol Cell Biol (2004) 0.86
Enhancement of docetaxel-induced cytotoxicity and apoptosis by all-trans retinoic acid (ATRA) through downregulation of survivin (BIRC5), MCL-1 and LTbeta-R in hormone- and drug resistant prostate cancer cell line, DU-145. J Exp Clin Cancer Res (2008) 0.85
Retinoic Acid Induces Apoptosis of Prostate Cancer DU145 Cells through Cdk5 Overactivation. Evid Based Complement Alternat Med (2012) 0.84
Differential effects of 9-cis and all-trans retinoic acid on the induction of retinoic acid receptor-beta and cellular retinoic acid-binding protein II in human neuroblastoma cells. Biochem J (1994) 0.83
Retinoic acid receptor alpha mediates growth inhibition by retinoids in rat pancreatic carcinoma DSL-6A/C1 cells. Br J Cancer (1998) 0.83
Cellular distribution of retinoic acid receptor-alpha protein in serous adenocarcinomas of ovarian, tubal, and peritoneal origin: comparison with estrogen receptor status. Am J Pathol (1998) 0.83
Modulation of the insulin-like growth factor-I system by N-(4-hydroxyphenyl)-retinamide in human breast cancer cell lines. Br J Cancer (1998) 0.82
All-trans retinoic acid decreases susceptibility of a gastric cancer cell line to lymphokine-activated killer cytotoxicity. Br J Cancer (1997) 0.81
E2F1 impairs all-trans retinoic acid-induced osteogenic differentiation of osteosarcoma via promoting ubiquitination-mediated degradation of RARα. Cell Cycle (2014) 0.81
Clinical efficacy of all-trans retinoic acid for treating adult T cell leukemia. J Cancer Res Clin Oncol (2007) 0.79
Bcl-2 accelerates retinoic acid-induced growth arrest and recovery in human gastric cancer cells. Biochem J (2000) 0.79
Positive impact of retinyl palmitate in leukoplakia of the larynx. Eur Arch Otorhinolaryngol (1997) 0.78
Antiproliferative effect of retinoid compounds on Kaposi's sarcoma cells. J Clin Invest (1994) 0.78
Effects of retinoic acid isomers on apoptosis and enzymatic antioxidant system in human breast cancer cells. Nutr Res Pract (2009) 0.78
Chmp 1A is a mediator of the anti-proliferative effects of all-trans retinoic acid in human pancreatic cancer cells. Mol Cancer (2009) 0.77
Interferon alpha plus 13-cis-retinoic acid modulation of BCL-2 plus paclitaxel for recurrent small-cell lung cancer (SCLC): an Eastern Cooperative Oncology Group study (E6501). Cancer Chemother Pharmacol (2014) 0.77
Pseudotumor cerebri presenting with visual failure in promyelocytic leukemia: a case report. J Med Case Rep (2012) 0.77
RB2/p130 ectopic gene expression in neuroblastoma stem cells: evidence of cell-fate restriction and induction of differentiation. Biochem J (2001) 0.77
Trial of isotretinoin and calcitriol monitored by CA 125 in patients with ovarian cancer. Br J Cancer (1996) 0.77
Retinoids in the treatment of glioma: a new perspective. Cancer Manag Res (2012) 0.77
Genetic selection for modulators of a retinoic-acid-responsive reporter in human cells. Genetics (2003) 0.77
An Eastern Cooperative Oncology Group phase I trial of all-trans-retinoic acid and interferon-alpha: E2Y92. Invest New Drugs (1997) 0.76
First chemical feature-based pharmacophore modeling of potent retinoidal retinoic acid metabolism blocking agents (RAMBAs): identification of novel RAMBA scaffolds. Eur J Med Chem (2011) 0.75
The role of human melanoma cell ICAM-1 expression on lymphokine activated killer cell-mediated lysis, and the effect of retinoic acid. Br J Cancer (1999) 0.75
Oncology. Postgrad Med J (1993) 0.75
Fenretinide (4-HPR) Targets Caspase-9, ERK 1/2 and the Wnt3a/β-Catenin Pathway in Medulloblastoma Cells and Medulloblastoma Cell Spheroids. PLoS One (2016) 0.75
Adverse effects of highdose vitamin A during radiotherapy. Eur Arch Otorhinolaryngol (1997) 0.75
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med (2000) 7.55
Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J Natl Cancer Inst (1994) 7.20
Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. JAMA (1994) 6.36
Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med (2001) 4.83
Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol (1995) 4.42
Unique allelic restriction fragments of the human Ha-ras locus in leukocyte and tumour DNAs of cancer patients. Nature (1985) 4.02
The origin of the chemiluminescence of phagocytosing granulocytes. J Clin Invest (1976) 2.92
Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol (1993) 2.28
Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol (2007) 2.17
Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. J Natl Cancer Inst (1996) 2.12
Representation of older patients in cancer treatment trials. Cancer (1994) 2.06
Correlates of response to IL-2 therapy in patients treated for metastatic renal cancer and melanoma. Cancer J Sci Am (2006) 1.89
Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells. N Engl J Med (1988) 1.82
13-cis-retinoic acid and interferon alpha-2a: effective combination therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst (1992) 1.81
Complications of cancer immunotherapy with levamisole. Lancet (1977) 1.76
The National Cancer Institute audit of the National Surgical Adjuvant Breast and Bowel Project Protocol B-06. N Engl J Med (1995) 1.74
Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countries. N Engl J Med (1994) 1.71
HLA associations in the antitumor response against malignant melanoma. J Immunother Emphasis Tumor Immunol (1995) 1.71
Chronic toxicity and oncogenicity study on acrylamide incorporated in the drinking water of Fischer 344 rats. Toxicol Appl Pharmacol (1986) 1.70
Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol (1988) 1.56
Nosocomial sepsis associated with interleukin-2. Ann Intern Med (1990) 1.56
Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J Clin Oncol (1996) 1.52
The area and volume of single human erythrocytes during gradual osmotic swelling to hemolysis. Can J Physiol Pharmacol (1970) 1.50
Phase II trial of oral vorinostat (suberoylanilide hydroxamic acid) in relapsed diffuse large-B-cell lymphoma. Ann Oncol (2008) 1.49
Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. J Clin Oncol (1993) 1.44
The maturation of differentiation therapy. N Engl J Med (1992) 1.44
Anticancer drug discovery and development throughout the world. J Clin Oncol (2002) 1.42
Comorbid psychopathology in binge eating disorder: relation to eating disorder severity at baseline and following treatment. J Consult Clin Psychol (2000) 1.40
Levamisole as adjuvant therapy for melanoma: quo vadis? J Clin Oncol (1991) 1.40
Recombinant interferon-alpha2b added to oral cyclophosphamide either as induction or maintenance in treatment-naive follicular lymphoma: final analysis of CALGB 8691. Leuk Lymphoma (2009) 1.39
Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol (1993) 1.37
EPOCH chemotherapy: toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol (1993) 1.34
A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol (1989) 1.28
Quality-of-life assessment in cancer treatment protocols: research issues in protocol development. J Natl Cancer Inst (1992) 1.28
Cogan's syndrome: a systemic vasculitis. Am J Med (1976) 1.26
Clinical trials in primary hepatocellular carcinoma: current status and future directions. Cancer Treat Rev (1988) 1.25
The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol (1972) 1.24
Thalamo-cortical processing of vibrissal information in the rat. I. Intracortical origins of surround but not centre-receptive fields of layer IV neurones in the rat S1 barrel field cortex. J Comp Neurol (1991) 1.21
The oxidative killing mechanisms of the neutrophil. Prog Clin Immunol (1977) 1.21
Primary hepatocellular cancer--present results and future prospects. Int J Radiat Oncol Biol Phys (1983) 1.20
Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH. J Clin Oncol (2000) 1.19
High-dose aldesleukin in renal cell carcinoma: long-term survival update. Cancer J Sci Am (1997) 1.15
Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience. Semin Oncol (1987) 1.15
The differential effects of human leukocyte pyrogen/lymphocyte-activating factor, T cell growth factor, and interferon on human natural killer activity. J Immunol (1982) 1.15
Antineoplastic activity of cannabinoids. J Natl Cancer Inst (1975) 1.14
Human restriction fragment length polymorphisms and cancer risk assessment. J Cell Biochem (1986) 1.12
1991 national survey of carcinoma of the breast by the Commission on Cancer. J Am Coll Surg (1994) 1.09
Accrual to clinical trials. J Natl Cancer Inst (1988) 1.09
National Cancer Institute's evaluation of unconventional cancer treatments. J Natl Cancer Inst (1992) 1.08
Inhibitory effects of elevated temperature on human cytokine production and natural killer activity. Cancer Res (1986) 1.08
Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev (1980) 1.07
Neonatal parathyroid function: role of gestational age and postnatal age. J Pediatr (1973) 1.06
Regulation of human blood erythroid burst-forming unit (BFU-E) proliferation by T-lymphocyte subpopulations defined by Fc receptors and monoclonal antibodies. Blood (1982) 1.06
Tamoxifen: trials, tribulations, and trade-offs. J Natl Cancer Inst (1994) 1.05
A variable tandem repeat locus mapped to chromosome band 10q26 is amplified and rearranged in leukocyte DNAs of two cancer patients. Nucleic Acids Res (1986) 1.04
Basophilic stippling of red blood cells: a nonspecific finding of multiple etiology. Am J Ind Med (1984) 1.04
A phase I/II study of galiximab (an anti-CD80 monoclonal antibody) in combination with rituximab for relapsed or refractory, follicular lymphoma. Ann Oncol (2007) 1.03
A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol (1986) 1.02
Levamisole: known effects on the immune system, clinical results, and future applications to the treatment of cancer. J Clin Oncol (1991) 1.02
Human hypervariable sequences in risk assessment: rare Ha-ras alleles in cancer patients. Environ Health Perspect (1987) 0.99
Chronic lymphocytic leukemia: staging and prognostic factors. Semin Oncol (1998) 0.98
The systemic administration of intravenous melphalan. J Clin Oncol (1988) 0.98
Doxorubicin cardiotoxicity. Serial endomyocardial biopsies and systolic time intervals. JAMA (1978) 0.98
Defective binding of the third component of complement (C3) to Streptococcus pneumoniae in multiple myeloma. Blood (1984) 0.97
5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)--a new antitumor agent with activity against malignant melanoma. Eur J Cancer (1972) 0.97
Insurance coverage of patients with breast cancer in the 1991 commission on cancer patient care evaluation study. Ann Surg Oncol (1994) 0.96
Evolution of time coding systems. Neural Comput (1999) 0.96
Inhibition by aflatonin B-1 of hydrocortisone induction of rat liver tryptophan pyrrolase and tyrosine transaminase. Arch Biochem Biophys (1968) 0.95
Immunologic abnormalities in HRS/J mice. I. Specific deficit in T lymphocyte helper function in a mutant mouse. J Immunol (1980) 0.95
Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials. J Clin Oncol (1991) 0.95
Metabolism, disposition and excretion of [14C]melamine in male Fischer 344 rats. Food Chem Toxicol (1983) 0.95
Strategy and planning for chemopreventive drug development: clinical development plans II. J Cell Biochem Suppl (1996) 0.94
2'-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug. Ann Intern Med (1988) 0.94
Antisense oligonucleotides as therapeutics for malignant diseases. Semin Oncol (1997) 0.94
Hepatic arterial chemotherapy for colorectal cancer metastatic to the liver. Ann Intern Med (1984) 0.93
The Non-Hodgkin Lymphoma Pathologic Classification Project. Long-term follow-up of 1153 patients with non-Hodgkin lymphomas. Ann Intern Med (1988) 0.93
Phase I evaluation of recombinant interleukin-2 in patients with advanced malignant disease. J Clin Oncol (1986) 0.93
Fludarabine phosphate: a synthetic purine antimetabolite with significant activity against lymphoid malignancies. J Clin Oncol (1991) 0.93
Clinical trials referral resource. Clinical trials of MGI-114. Oncology (Williston Park) (1999) 0.93
A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol (1985) 0.92
Building quality of life assessment into cancer treatment studies. Oncology (Williston Park) (1992) 0.92
HLA association with response and toxicity in melanoma patients treated with interleukin 2-based immunotherapy. Cancer Res (1992) 0.92
Metabolism of benzophenone-3 in rats. Drug Metab Dispos (1993) 0.91
Systemic treatment of advanced and recurrent endometrial carcinoma: current status and future directions. J Clin Oncol (1991) 0.91
Paclitaxel activity in heavily pretreated breast cancer: a National Cancer Institute Treatment Referral Center trial. J Clin Oncol (1995) 0.91
Rapid gastric absorption of sodium nitrite in mice. J Pharm Sci (1972) 0.91
Immunodominance across HLA polymorphism: implications for cancer immunotherapy. J Immunother (1998) 0.91
Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcγRIIIa-158 V/F polymorphism. Ann Oncol (2010) 0.90
Pharmacokinetics of benzophenone-3 after oral exposure in male rats. J Appl Toxicol (1995) 0.90
Disposition of benzophenone-3 after dermal administration in male rats. Toxicol Lett (1994) 0.89
Relationship between acrylamide reproductive and neurotoxicity in male rats. Reprod Toxicol (2000) 0.89
Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. J Clin Oncol (1987) 0.89
Morphological surface changes in the terminal bronchiolar region of NO2-exposed rat lung. Environ Res (1973) 0.89
1-Aminobenzotriazole inhibits acrylamide-induced dominant lethal effects in spermatids of male mice. Mutagenesis (2000) 0.88
Estrogen receptors in male breast cancer: clinical and pathologic correlations. Cancer (1981) 0.88
Cephalotaxine esters: antileukemic advance or therapeutic failure? J Natl Cancer Inst (1988) 0.88